La vendita allo scoperto per Codexis dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Codexis. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Codexis (NASDAQ:CDXS) Azioni, Report sulle vendite allo scoperto

Codexis

Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.

Codexis Inc

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $11.0, with a high estimate of $11.00 and a low estimate of $11.00. This current average is unchanged from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1732287644_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Codexis among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Codexis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Codexis compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Codexis's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CDXS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Codexis analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Codexis: A Closer Look</h2>
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
<h3>Financial Insights: Codexis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Codexis's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 38.33%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -160.84%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Codexis's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -30.61%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Codexis's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -14.73%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.57, Codexis adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CDXS

Deep Dive Into Codexis Stock: Analyst Perspectives (4 Ratings)

Cantor Fitzgerald analyst Kristen Kluska reiterates Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) with a Overweight and maintains $11 price target.

News

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Codexis, Maintains $11 Price Target

—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset—
—Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared to wild-type enzymes—
—Management to host conference call today at 4:30 pm EST to discuss data—
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from three presentations at the TIDES Europe annual meeting being held November 12-14, 2024, in Hamburg, Germany. The data demonstrate the Company's rapid advancement of its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis&#x2122; manufacturing platform and establish Codexis' position at the forefront of enzymatic synthesis technology to enable to ongoing expansion of RNAi therapeutics.

Biotech

General

Codexis Unveils Pioneering Enzymatic Synthesis Data To Enable The Future Manufacturing Of RNAi Therapeutics; Management Hosted Conference Call Today At 4:30 pm EST To Discuss Data

Benchmark analyst Robert Wasserman reiterates Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) with a Hold.

Benchmark Reiterates Hold on Codexis

WIIM

Codexis shares are trading higher after the company reported better-than-expected Q3 revenue results.

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) affirms FY2024 sales outlook from $56.00 million-64.00 million to $56.00 million-64.00 million.

Guidance

Codexis Affirms FY2024 Product revenues $38M-$42M, R&D revenues $18M-$22M.

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.23) by 26.09 percent. The company reported quarterly sales of $12.833 million which beat the analyst consensus estimate of $11.482 million by 11.77 percent. This is a 38.33 percent increase over sales of $9.277 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Codexis Q3 2024 GAAP EPS $(0.29) Misses $(0.23) Estimate, Sales $12.833M Beat $11.482M Estimate

Management

Codexis Says Sriram Ryali Ceased To Serve As CFO And Principal Financial And Accounting Officer Effective As Of September 30, 2024

These funds are in addition to the&nbsp;$73.2 million&nbsp;in cash, cash equivalents and investments on hand as of June 30, 2024.&nbsp;In addition to the financing, the Company strengthened its management team through the appointments of Alison Moore&nbsp;to the newly created role of Chief Technology Officer and Georgia Erbez as Chief Financial Officer.

Codexis Reports Increase In Its Cash Reserves Through Capital Raises Totaling $31M Via Existing ATM Facility, Bringing Cash Runway Into 2027; Georgia Erbez Named As CFO

Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading enzyme engineering company, today announced it has entered into a non-exclusive commercial and manufacturing license agreement with Alphazyme LLC, part of Maravai LifeSciences, for multiple enzymes in Codexis' life science enzyme portfolio. The agreement includes licenses for the HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes that were in development directed towards genomics and diagnostics applications prior to the Company's strategic shift announced in July 2023. Under the terms of the agreement, Codexis is eligible to receive sales-based royalties. &nbsp;
"As our manufacturing partner for the past three years—and with an existing genomics enzyme portfolio and sales force —Alphazyme is the natural choice to extend our commercial reach into this segment. We anticipate a smooth transition for our customers as there is no change in manufacturing supply and many of our customers are already familiar with the Alphazyme team," said Kevin Norrett, MBA, Chief Operating Officer at Codexis. "This transaction enables Codexis to maintain its focus on maximizing our near-term commercial opportunities and strategic priorities. This includes the growth of our Pharmaceutical Manufacturing business, increasing commercial adoption of the dsRNA ligase, and the build-out of our ECO Synthesis&#x2122; Innovation Lab to support manufacturing process development for our customers' preclinical siRNA assets. We remain on track to achieve key milestones for the ECO Synthesis&#x2122; platform this fiscal year, while delivering double-digit product revenue growth and maintaining a path to positive cash flow around the end of 2026."
Alphazyme is a premier partner for industrial-scale molecular biology enzymes. Alphazyme enthusiastically collaborates with manufacturers of nucleic acid synthesis and detection platforms to produce affordable, custom enzyme formulations of the highest quality that meet the specifications of the rapidly expanding markets for custom DNA and RNA molecules, genomic medicines and genetic testing.&nbsp;"The Codexis and Alphazyme relationship has been strong for many years. We are excited to take on Codexis' portfolio of high-performing life science and diagnostic enzymes and be a part of their continued success," said Chad Decker, Vice President and General Manager of Alphazyme. This new collaboration will leverage the experience and industry knowledge of the Alphazyme team to enhance the commercialization of Codexis' portfolio of life science and diagnostic enzymes.
This license agreement marks another transaction in which Codexis is executing on its strategy to divest the Company's non-core assets following its strategic shift to focus on the growth of its Pharmaceutical Manufacturing business and Enzyme Catalyzed Oligonucleotide (ECO) Synthesis&#x2122; manufacturing platform.

MRVI

Codexis Licenses Key Enzymes to Alphazyme, Sharpening Focus on Pharmaceutical Growth

Benchmark analyst Robert Wasserman downgrades Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) from Buy to Hold.

Downgrades

Benchmark Downgrades Codexis to Hold

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.25) by 28 percent. The company reported quarterly sales of $7.979 million which beat the analyst consensus estimate of $7.825 million by 1.97 percent. This is a 62.58 percent decrease over sales of $21.323 million the same period last year.

Codexis Q2 2024 GAAP EPS $(0.32) Misses $(0.25) Estimate, Sales $7.979M Beat $7.825M Estimate

Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company's investigational Fabry and Pompe disease compounds. Under the terms of the agreement, Codexis is eligible to receive future development and commercial milestone payments in addition to a low-to-mid single-digit percentage net sales-based royalty. &nbsp;

Contracts

Codexis Finalizes Purchase Agreement With Crosswalk Therapeutics For Gene Therapy Assets; Codexis Is Eligible To Receive Future Development And Commercial Milestone Payments In Addition To A Low-To-Mid Single-Digit Percentage Net Sales-Based Royalty

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) with a Overweight rating and announces Price Target of $11.

Initiation

Cantor Fitzgerald Initiates Coverage On Codexis with Overweight Rating, Announces Price Target of $11

Health Care

Codexis Successfully Synthesizes An Oligonucleotide Via An Enzymatic Route To Support RNA-Based Therapeutics Manufacturing

Benchmark analyst Robert Wasserman reiterates Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) with a Buy and maintains $9 price target.

Benchmark Reiterates Buy on Codexis, Maintains $9 Price Target

Reports Q3 revenue $12.83M, consensus $11.48M. "Codexis (CDXS) had a strong third quarter, in which we surpassed product revenue goals, welcomed tw...

Codexis reports Q3 EPS (29c), consensus (24c)

Codexis, Inc. 2024 Q3 - Results - Earnings Call Presentation

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Codexis ( ($CDXS) ) has released its Q3 earnings. Here is a breakdown of the information Codexis presented to its investors. Codexis, Inc., a promi...

Codexis Reports Strong Q3 Revenue Growth

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Codexis (CDXS – Research Report) today and set a price target of $5.00. The company...

Codexis (CDXS) Receives a Buy from Stifel Nicolaus

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Codexis (CDXS – Research Report). The company's shares closed ...

Codexis (CDXS) Gets a Buy from Craig-Hallum

An update from Codexis ( ($CDXS) ) is now available. Codexis, Inc. has appointed Raymond De Vré as a new Class I director to its Board, enhancing i...

Codexis Strengthens Board and Updates Bylaws

TD Cowen analyst Brendan Smith maintained a Hold rating on Codexis (CDXS – Research Report) today and set a price target of $3.00. The company's sh...

Codexis (CDXS) Receives a Hold from TD Cowen

In a report released today, Daniel Arias from Stifel Nicolaus maintained a Buy rating on Codexis (CDXS – Research Report), with a price target of $...

Stifel Nicolaus Remains a Buy on Codexis (CDXS)

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Codexis (CDXS – Research Report), with a price tar...

Comments

Codexis

Vendite allo scoperto

Codexis (NASDAQ:CDXS) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO